Novartis and BioArctic Partner on $30 Million Deal to Develop Therapies for Neurological Disorders

Novartis and BioArctic Partner on $30 Million Deal to Develop Therapies for Neurological Disorders

Novartis and BioArctic have entered into an agreement t […] The post Novartis and BioArctic Partner on $30 Million Deal to Develop Therapies for Neurological Disorders first appeared on GeneOnline News. The post Novartis and BioArctic Partner on $30 Million Deal to Develop Therapies for Neurological Disorders appeared first on GeneOnline News.

Novartis and BioArctic sign collaboration agreement on BrainTransporter technology for neurological drug development - Express Pharma

Novartis will evaluate the data generated during the initial collaboration with BioArctic and decide whether to exercise its option to license any drug candidate developed under the agreement. If Novartis exercises this option, BioArctic will be eligible to receive additional payments of up to USD 772 million. BioArctic will also be entitled to tiered mid-single digit royalties on future global product sales if the product reaches the market. Un…